Ann: Appendix 4C - September 2019 Quarterly Report, page-14

A quick summary of the Quarterly & things that caught my attention (just a couple):

Data to be unblinded & statistical analysis performed simultaneously by Janssen & PIQ, results expected by Q3 FY 2020 (not Q3 2020, easy to read wrong), not so far away. The company are excited by the potential transformative results (analysis by both companies) to fast track commercialisation of PromarkerD (EU & USA?), designation as a CDx, not just for Janssen drug (Invokana) but also for several drugs in the glifozin class.

FDA approvals for applications are pending as we speak. PromarkerD is already independently validated, but this data will ramp things up a notch for us if efficacy is shown for this class of drugs.

A lot going on with PromarkerD going live in Spain with Patia & technology transfer to Atturos to enable PromarkerD roll out in EU with new partners. Show casing at EASD annual conference of PromarkerD is a big thing, a peak body for Diabetes in Europe.

Regarding Endometriosis: I agree, it would be wonderful to have that testing technology right now (as it’s much needed), there have been new Big Pharma drugs come out recently for chronic Endo pain, it’s currently diagnosed by laparoscopy, and a common & nasty disease. There must be revenue to continue to fund this first. It’s just the sensible thing to do right now.

Giardia: This is one of the most common intestinal diseases on the planet, not just in the third world, think Boil water alerts even in Australia & all over the world. Animals are the reservoir for this disease, pets can also be a hazard to human health also.

This seems to be far more advanced in a second POC study with prototype testing of an Immunoessay version of the test - that is STRAIN specific, in collaboration with Murdoch Uni Veterinary School & A LEADING US VETERINARY CO & envisaged to detect issues with human health with pets. It seems the partnerships on this clinical need are already in place. Not to say that won’t happen with Endometriosis in the reasonably short term with developments in this also common disease.

Not disappointed at all, we are in the midst of a shift in how DKD/CKD is treated & current standards of care. We know there are currently working parties on this globally & involve KOL (key opinion leaders). Dr Richard Lipscombe has been invited in the USA to be one of those special people. It’s very early days after the the only approval so far exactly a month ago for CKD in diabetes. Let’s get this functioning first & making good revenue first with recent drug developments, before we even look deeper into the pipeline. GLTAH